Regeneron to Present Ordspono Trial Results at ASH
Regeneron plans to present trial results for Ordspono in relapsed or refractory marginal zone lymphoma at ASH.
Regeneron plans to present trial results for Ordspono in relapsed or refractory marginal zone lymphoma at ASH.